HLS Therapeutics Inc T.HLS

Alternate Symbol(s): HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.

TSX:HLS - Post by User

HLS Therapeutics Inc

Bullboard Posts

Comment by Pat123on Mar 29, 2018 11:43pm

97 Views

Post# 27807022

RE:Results are in, and we are still screwed!

Agree 100%

On sedar they posted AM 2017 results under HLS. Look at the Other documents on March 29th

Ouch! They have burned cash big time in Q4 and autorized in November 2017 a nice compensation to the remaining management. Also, $2M in professional fees in 2017 only. Probably more coming for the first 2 months of 2018.

By looking at 2015 results as well, they have burned $4-5M in cash (paying management and professional fees). That's a lot for an empty shell.

Now, I realize that only the lawyers/advisers and the management (mainly M.Nutt) will collect from the GM settlement. Don't forget that they offer $2.65 to buyback shares in Sep 2015.

Bullboard Posts

Sirios Resource discovers visible gold in Quebec